Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium
- Development stage
- Unknown
- Lead developer
- BIFIDO
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium is a probiotic biologic being evaluated as a therapeutic intervention for major depressive disorder, particularly in hospitalized adolescents. Investigated by researcher Zhen-Hong Hu, the treatment is typically administered orally in capsule form and often used in combination with high-frequency repetitive transcranial magnetic stimulation (rTMS). The mechanism of action involves modulation of the gut-brain axis, where the bacteria alter the gut microbiota composition, stimulate the production of neurotransmitters such as serotonin, and reduce systemic inflammatory cytokines. Clinical trial data (ISRCTN16752763) indicates that an 8-week regimen of Bifidobacterium combined with rTMS significantly improves depressive symptoms as measured by the HAMD-24 scale.
- Other names
- Bifidobacterium probiotic
02
Targets
IL10 (Interleukin-10)
Beyond the preview
Go deeper on Bifidobacterium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium.